PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.36%
Negative revenue growth while ENPH stands at 13.94%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-33.63%
Negative gross profit growth while ENPH is at 0.83%. Joel Greenblatt would examine cost competitiveness or demand decline.
-110.42%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-105.75%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-111.73%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-111.98%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-113.46%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.55%
Share reduction more than 1.5x ENPH's 3.40%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-14.46%
Reduced diluted shares while ENPH is at 0.31%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-367.05%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-441.53%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-61.76%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-36.20%
Negative 5Y CAGR while ENPH stands at 65.62%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-35.97%
Negative 3Y CAGR while ENPH stands at 200.27%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
86.97%
10Y OCF/share CAGR at 75-90% of ENPH's 105.44%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
91.25%
Below 50% of ENPH's 275.03%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
85.82%
3Y OCF/share CAGR under 50% of ENPH's 1471.13%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-1185.23%
Negative 10Y net income/share CAGR while ENPH is at 102.20%. Joel Greenblatt sees a major red flag in long-term profit erosion.
54.60%
Below 50% of ENPH's 159.35%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
65.83%
Below 50% of ENPH's 530.39%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-87.55%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-78.76%
Negative 5Y equity/share growth while ENPH is at 909.02%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-38.27%
Negative 3Y equity/share growth while ENPH is at 1738.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.32%
AR growth is negative/stable vs. ENPH's 29.60%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
9.55%
We show growth while ENPH is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-3.14%
Negative asset growth while ENPH invests at 82.83%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-11.71%
We have a declining book value while ENPH shows 46.43%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
4.40%
Debt shrinking faster vs. ENPH's 204.35%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
53.13%
R&D growth drastically higher vs. ENPH's 38.08%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-9.08%
We cut SG&A while ENPH invests at 47.08%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.